Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners within the industry. The company was founded in 2014 and is based in Malmö.

Quotes for Aptahem AB

Right Now

+/-
0
%
0,00%
Latest
0.88
High
0.88
Low
0.832
Volume
14 171
Turnover (SEK)
12 465
Market Value (MSEK)
11,0
Time (Latest trade)

Board

CEO

  • Mikael Lindstam

Chairperson of the Board

  • Bert Junno

Board

  • Johan Lindh
  • Mikael Lindstam
  • Theresa Comiskey Olsen

Videos

Largest Owners

Name Capital % Votes % Date
Investment Aktiebolaget Balticum 8,10 8,10 2024-12-23
Avanza Pension 7,34 7,34 2024-12-23
Tuvedalen Ltd 5,18 5,18 2024-12-23
Ivar Nordqvist 3,61 3,61 2024-12-23
Fenja Capital Partners A/S 2,82 2,82 2024-12-23
Nordnet Pensionsförsäkring 2,05 2,05 2024-12-23
Magnus Renck 1,90 1,90 2024-12-23
Marcus Milerud 1,81 1,81 2024-12-23
Klas Göran Viktor Strömberg 1,27 1,27 2024-12-23
Peter Cederström 1,16 1,16 2024-12-23
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream